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Long-term colonisation with donor
bacteriophages following successful faecal
microbial transplantation
L. A. Draper1†, F. J. Ryan1,2†, M. K. Smith1, J. Jalanka3, E. Mattila4, P. A. Arkkila4, R. P. Ross1, R. Satokari3* and C. Hill1*
Abstract
Background: Faecal microbiota transplantation (FMT) is used in the treatment of recurrent Clostridium difficile
infection. Its success is typically attributed to the restoration of a diverse microbiota. Viruses (including
bacteriophages) are the most numerically dominant and potentially the most diverse members of the microbiota,
but their fate following FMT has not been well studied.
Results: We studied viral transfer following FMT from 3 donors to 14 patients. Recipient viromes resembled those
of their donors for up to 12 months. Tracking individual bacteriophage colonisation revealed that engraftment of
individual bacteriophages was dependent on specific donor-recipient pairings. Specifically, multiple recipients from
a single donor displayed highly individualised virus colonisation patterns.
Conclusions: The impact of viruses on long-term microbial dynamics is a factor that should be reviewed when
considering FMT as a therapeutic option.
Keywords: Faecal microbiota transplantation, Bacteriophages, Viruses, Engraftment, Persistence, Donor-recipient
Background
The human gut houses a densely populated microbial
ecosystem that includes bacteria, archaea, protozoa, and
fungi, as well as their viruses. These coexist in a dynamic
but stable equilibrium in healthy individuals [1]. Disrup-
tion of this complex ecosystem has been associated with
numerous diseases [2], for example antibiotic treatment
can potentially lead to recurrent Clostridium difficile in-
fection (rCDI). Faecal microbiota transplantation (FMT)
involves the infusion of a faecal slurry from a healthy
donor to the duodenum, caecum, or colon of a recipient
in an attempt to restore microbiota diversity and com-
position. FMT is used in clinical practice and has a re-
ported 80–90% success rate in treating rCDI [3]. It has
been shown that bacterial transfer occurs in a
donor-specific manner and that the new resident species
can be retained for up to 1 year post-FMT [4].
Numerically, the most predominant component of the
gut microbiome is bacteriophages, which may be 20
times more abundant than bacteria in mucosal samples
[5, 6]. These bacteriophages play an essential role in
population dynamics in aquatic environments and pre-
sumably have similar effects in the gut microbial ecosys-
tem. To date, only limited investigations into the
long-term transplantation of bacteriophages following
FMT have been performed. These include two rCDI case
studies spanning 6–7 months post-FMT [7, 8] and a ~
3.5-month study following the unsuccessful FMT treat-
ment of three paediatric ulcerative colitis patients [9].
Resolution of rCDI is the primary goal of FMT treat-
ment, but in order to generate a more reproducible
treatment regime, significant efforts have been devoted
to identifying a more defined group of bacterial species
that could replace FMT. Petrof et al. [10] succeeded in
disease resolution for up to 6 months in 2 patients using
a combination of 33 bacterial isolates recovered from a
healthy donor stool sample. However, Ott et al. [11] have
shown that in a small study involving 5 patients, a sterile
faecal filtrate from which cellular microbes (but not bac-
teriophages) were removed also had the ability to resolve
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rCDI. Moreover, Zuo et al. [8] found that treatment re-
sponse in FMT was associated with a high colonisation
level of donor-derived Caudovirales taxa in the recipient
and concluded that Caudovirales may play a role in the
efficacy of FMT in rCDI. The current study is the first
to investigate long-term engraftment of bacteriophages
following successful FMT treatment of rCDI patents.
The study includes 3 donors and 14 recipients from a
recent study involving patients with rCDI [4], the major-
ity of which were monitored for up to 1 year and reveals
that the transfer and persistence of bacteriophages in
the human gut are specific to each donor-recipient pair.
Results and discussion
Shotgun metagenomics was used to analyse the viromes
of these donors and recipients. This corresponded to
134 faecal samples collected for 14 recipient patients
pre-FMT and at intervals up to 1-year post-FMT, as well
as samples from each of the 3 donors collected at the
corresponding time points. From 2 recipients (P11 and
P14), no pre-FMT sample was available, while some
post-FMT samples were unavailable for 3 recipients.
Metadata corresponding to these donors and recipients
can be found in Additional file 1: Table S1 and in the
original study examining the bacteriome of these indi-
viduals [4]. Viral DNA was sequenced on an Illumina
HiSeq to a mean depth of 1,277,374 paired-end reads
per sample and assembled with metaSPAdes. In order to
avoid contamination with bacterial DNA, confounding
estimates of viral transfer, only those contigs that con-
tained known viral genes or were predicted as viral with
VirSorter [12] were used for further analysis resulting in
a total of 7064 metagenomic viral contigs with a mean
length of 4.9 kb containing an average of 5.7 known viral
genes per contig. The bacteriophage community was
dominated by dsDNA and ssDNA phages. The majority
of RNA viruses found in the gut are plant and human vi-
ruses [13], and thus, these were not investigated here, as
the current study focused on DNA containing viral par-
ticles of the virome. Nonetheless, the impact and in-
volvement of eukaryote and other RNA viruses are of
interest, especially as it has been previously reported that
the eukaryotic virome in the gut is altered post-FMT in
ulcerative colitis (UC) patients [14]. Whether this is
UC-specific phenomenon or a general effect of FMT is
yet to be established.
The impact of FMT on the DNA virome beta diversity
was measured using Bray-Curtis distance. Principal co-
ordinate analyses of the virome demonstrated that FMT
resulted in gut virome remodelling in a donor-specific
fashion with each set of donor-recipient groups forming
distinct groups centred on the donor (Fig. 1a), strikingly
more distinct than that observed based on bacterial pro-
files as measured with 16S (Fig. 1b). In order to examine
the level of donor-recipient similarity over time, we plot-
ted the Spearman correlation between each recipient
sample and its donor sample at each time point, the cor-
relation between recipients and their own pre-FMT
(rCDI) sample, and their correlation with other donors
and finally donor similarity over time to their own T-0
sample (Fig. 1c). We found that for 2 months post-FMT,
the recipient’s viromes were significantly more similar to
that of their donors than it was to their own pre-FMT vir-
ome (Wilcoxon rank sum test, P = 0.01288). Moreover, for
up to 12months post-FMT, the recipients were found to
be equally similar to their own pre-FMT sample and their
donor’s sample. This demonstrates a lasting shift in the re-
cipient gut virome towards a donor-specific one, and given
that bacteriophages are usually strain-specific, this pre-
sumably reflects a long-term alteration to the fine struc-
ture of the microbiome.
Recurrent CDI is marked by changes in the gut virome
relative to healthy controls [8]. We investigated the
abundance of viral taxonomic groups by utilising a read
classification approach based on amino acid similarity to
the Non-Redundant (nr) database at NCBI [15]. The vast
majority of classifiable reads were identified as being
from the Caudovirales and Microviridae taxa, indicating
the samples were predominantly composed of bacterio-
phages as has been previously found with the human gut
virome [16]. In agreement with Zuo et al., we found that
rCDI is marked by a disturbance in the enteric gut vir-
ome characterised by increased Caudovirales (Wilcoxon
test, P = 0.0009806), decreased Microviridae (Wilcoxon
test, P = 0.01093), and increased Anelloviridae abun-
dance (Wilcoxon test, P = 0.04509) when compared to
our healthy donors. (Fig. 2). Furthermore, we have ex-
panded upon previous observations by demonstrating
that these differences are not only immediately resolved
by FMT but persist for at least 12 months (Fig. 2). We
also observed an increase in unclassified viruses
(Wilcoxon test, P = 0.00039) in the rCDI virome and ob-
served that these individuals have decreased levels of
CrAssphage (Wilcoxon test, P = 0.0005647) (Fig. 2),
which represents the most prominent group of bacterio-
phages in the human gut [17, 18]. This group of
CrAssphage-like bacteriophage is thought to primarily
predate on members of the phylum Bacteroidetes, which
has previously been described as decreased in the CDI
gut microbiota [19]. Jalanka et al. observed a 2.7-fold in-
crease in the members of the Bacteroidetes phylum in
this cohort related to Bacteroides vulgatus and Prevotella
oralis using 16S rRNA profiling [2]. No single bacterio-
phage, virus, viral family, or viral contig could be de-
tected as universally present post-FMT suggesting that
no single bacteriophage or DNA virus was responsible
for disease resolution. The only statistically significant
difference in viral richness or diversity was observed
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with a reduction in Chao1 richness in samples collected
at 2 weeks post-FMT when compared with the original
CDI patient samples (paired Wilcoxon rank sum test,
P = 0.0425, Additional file 2: Figure S1). This initial
fluctuation in richness post-FMT was also observed by
Zuo et al. [8], and we believe it may constitute an initial
loss of unique donor/recipient phages as a consequence
of loss of their bacterial host due to engraftment and
shifting of other members of the bacterial population
following FMT.
Chehound et al. [9] observed that certain temperate
bacteriophages were transferred with greater efficiency
than other members of the virome during FMT. We
aimed to assess the prevalence of integrase genes within
our viral contigs to determine the extent to which tem-
perate phages were transferred in this study. Of the set
of 7064 contigs assembled here, 916 could be classified
into a viral order or family, and 182 of these were found
to contain integrase genes. A further 486 contigs that
could not be classified to a known viral group also con-
tained a known integrase. Only 51 of these 1402 (916 +
486) were observed to be transferred from any donor to
any recipient at any time point; however, it is possible
many others were below the detection threshold. Thus,
our analysis indicates that the collective virome contains
at least several hundred temperate phages, and some of
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these are indeed transplanted. In addition to temperate
phage transfer, we also observed the transplantation of
lytic phages such as CrAssphage (deemed lytic as it
contains no known integrase gene and has not been
observed in bacterial genomes) and members of the
predominantly lytic Microviridae family [20]. We be-
lieve this strongly indicates that transfer of lytic bac-
teriophages occurs during FMT and that these either
transplanted with their host or acquired a new host
within the recipient’s microbiome.
Previous work has highlighted the differential colon-
isation of donor bacterial strains depending on the
donor-recipient pairing post-FMT [4, 21–24]. Thus, we
sought to explore viral colonisation across the 3 donors
and 12 recipients (those with pre-FMT samples) for up
to 1 year after treatment. Contig relative abundances
were summed by origin (transferred and non-transferred
contigs specific to the donor, unique recipient contigs,
those common to both, or those newly detected
post-FMT) (Fig. 3). We observed that the relative abun-
dance of transferred contigs (those absent in CDI sam-
ples, present in the donor sample, and present
post-FMT) is highly variable, ranging from almost the
entire sample to a fraction of a percent depending on
the donor-recipient pair. Individual’s viromes are highly
unique [25]; thus, engraftment would be expected and is
observed to be donor-specific (Fig. 1a). We therefore
sought to investigate the colonisation patterns of specific
bacteriophages. In all but one case, these phages were
absent from the recipient and are examples of donor
transfer but with differing recipient colonisation. A
number of bacteriophages, including a member of the
Microviridae family, a contig of 86 kb classified as a
Caudovirales, CrAssphage, and an unclassified viral
contig of 44 kb, none of which possess a known inte-
grase, were transferred to all recipients but with varying
degrees of engraftment and persistence over time (Fig. 4a,
b). It is possible that the abundance of these lytic phages
expands and contracts overtime due to fluctuations in
host populations. Moreover, in some FMT recipients,
high proportions of contigs were detected that were not
detected in either CDI samples or in the donor. This
suggests that these bacteriophages were either below the
threshold of detection at the earlier time points, were
the result of newly induced prophage, or were acquired
exogenously by recipients.
Given that all recipients here achieved clinical reso-
lution, it is impossible to ascertain what impact the col-
onisation of specific microbes played in the success of
each FMT treatment. One plausible explanation is that
a healthy, diverse, and stable ecosystem per se, even
without specific or prescribed microbial components,
can resolve rCDI. In such a scenario, bacteriophages
could play a crucial role in maintaining ecosystem sta-
bility. Research to date has not established any differ-
ence in rCDI resolution following the use of related or
unrelated healthy donor samples [26]. However, for
large-scale implementation of FMT and especially for
other indications, banks of screened faeces from
healthy donors provide a more logistically sound ap-
proach. As highlighted here, and in previous studies
[22], donor-recipient compatibility may be a key factor
in the extent and stability of microbial colonisation.
However, determination of donor-recipient microbiome
similarity and/or compatibility in relation to disease
resolution is still lacking. Virome analysis represents
another view of the microbiome that could improve the
selection of optimal donor-recipient pairs.
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Conclusion
The study of the role of the human microbiome on
health and disease has largely focused on its bacterial
component. A major success story has been the use of
FMT for rCDI treatment in clinical practice. There have
been conflicting reports in the literature as to what com-
ponent of the microbiome is responsible for the reso-
lution of rCDI, and the transfer of whole faecal material
has proved most successful across studies. Similarly, the
long-term effects of FMT on the microbiome and the
virome of the recipient, and thus on human gastrointes-
tinal health, are not well understood, with many studies
following patients for less than half a year. Here, we
demonstrate that the impact of a successful FMT on the
virome lasts for 12 months and can result in the
long-term colonisation of specific bacteriophages de-
pending on the donor-recipient pairing. Bacteriophages
are essential components of natural ecosystems and are
likely to have an important stabilizing role in the gut
ecosystem, too. We believe that those performing FMT
therapy should consider all components of the micro-
biome when considering the optimal outcome and
long-term health of their patients. Current donor eligi-
bility screening is usually based on medical history,
physical examination, and stool and blood screening
[26–28]. Such screening with respect to donor viral con-
tent is suggested to identify the presence of major
eukaryote viruses of note such as HIV, norovirus, adeno-
virus, rotavirus, and Epstein-Barr virus [26, 29], but this
is not exhaustive nor does it pertain to bacteriophage
content. Recent research has indicated that bacterio-
phages may play a role in gastrointestinal diseases such
as IBD and in the development and maintenance of a
healthy gut microbiome [30, 31], and thus, their transfer
may have long-term consequences for human health. It
is also worth noting, however, that up to 90% of
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sequences retrieved from a human virome are novel, or of
unknown function [32], and so the transfer of a significant
repertoire of unknown genetic information should also be
considered when performing FMT for non-life-threaten-
ing diseases. However, given the practicality that full meta-
genomic/virome analysis is not feasible nor recommended
in clinical practice at present [26], we believe that clini-
cians should continue, as they currently do so, to weigh
the expected benefits and potential risks carefully when
performing FMT, as, despite these current unknowns,
FMT is a highly effective treatment for rCDI. Investiga-
tions into phageome/virome transfer in FMT should how-
ever continue in a research setting so as to understand
more clearly the colonisation patterns and role of these
dominant members of the microbiota.
Materials and methods
Sample collection and storage
Faecal samples from 14 recurrent Clostridium difficile in-
fection (rCDI) patients and from 3 universal donors were
utilised in this study. Samples from donors and patients
were both pre- and post-FMT over a 1-year follow-up
period (Additional file 1: Table S1). The study was ap-
proved by the Ethics Committee of the Hospital District of
Helsinki and Uusimaa Finland (DnroHUS124/13/03/01/
11) [4]. All samples were stored at − 80 °C prior to analysis.
Virome DNA extraction and library preparation for MiSeq
Approximately 0.5 g of faecal sample was homogenised
in 10ml saline magnesium (SM) buffer (100 mM NaCl,
8 mM MgSO4, 50 mM Tris [pH 7.5]), followed by centri-
fugation twice at 5000g at 4 °C for 20 min. Resulting su-
pernatants were filtered twice through 0.45 μm syringe
filters to remove particulates and bacterial cells. NaCl
(0.5 M final concentration; Sigma) and 10% w/v poly-
ethylene glycol (PEG-8000; Sigma) were added to the
resulting filtrates, and these were incubated at 4 °C over-
night. Following centrifugation at 5000g at 4 °C for 20
min, the pellet was resuspended in 400 μl SM buffer. An
equal volume of chloroform (Fisher) was added, and
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following 30 s of vortexing, the sample was centrifuged
at 2500g for 5 min at RT. The aqueous top layer is
retained, and it was subjected to RNase I (8 U final con-
centration; Ambion) and DNase (20 U final concentra-
tion; TURBO DNA-free™ Kit, Invitrogen) treatment in
accordance with the manufacturer’s guidelines. To iso-
late DNA, the samples were incubated with 20 μL of
10% SDS and 2 μL of proteinase K (Sigma, 20 mg/mL)
for 20 min at 56 °C, prior to lysis by the addition of
100 μL of phage lysis buffer (4.5 M guanidine thiocyan-
ate, 45 mM sodium citrate; 250 mM sodium lauroyl sar-
cosinate; 562.5 mM β-mercaptoethanol; pH 7.0) with
incubation at 65 °C for 10 min. Viral DNA was purified
by two treatments with an equal volume of phenol to
chloroform to isoamyl alcohol (25:24:1) and passing the
resulting purified DNA through a QIAGEN Blood and
Tissue Purification Kit and eluting samples in 40 μL of
AE buffer (Qiagen). The DNA concentrations were
equalised prior to amplification using an Illustra Geno-
miPhi V2 kit (GE Healthcare). Amplifications of purified
viral DNA was performed in triplicate on all samples as
described by the manufacturer for a period of 16 h. Sub-
sequently, products from each of the triplicate reactions
and 12 μL of each corresponding original viral DNA
purification were pooled together and used for
paired-end Nextera XT library preparation (Illumina).
All samples were sequenced on an Illumina HiSeq at
GATC in Germany. Raw sequence data generated as part
of this research has been deposited in the Sequence
Read Archive under BioProject PRJNA446038.
Analysis of virome sequencing data
The quality of the raw reads was visualised with FastQC
v0.11.3 [33]. Nextera adapters were removed with cuta-
dapt v1.9.1 [34], followed by read trimming and filtering
with Trimmomatic v0.36 [35] to ensure a minimum
length of 60, maximum length of 250, and a sliding win-
dow that cuts a read once the average quality in a win-
dow size of four falls below a Phred score of 30. Reads
were classified against the Non-Redundant (nr) database
at NCBI as of December 4, 2017, using the Kaiju classi-
fier [15] which classifies based on amino acid sequence
similarity. Reads were also assembled on a per sample
basis with the metaSPAdes assembler [36]. Redundancy
between samples was removed by aligning all contigs
against each other with BLASTn as implemented in
BLAST+ v2.2.28 [37] keeping the longer contig, where a
hit was counted as at least 90% identity over 90% of their
length. In order for a contig to be included in the final
analysis, it must be detected as viral by Virsorter [12] in
the virome decontamination mode, or be at least 1 kb in
length and contain a gene from one known Prokaryotic
Virus Orthologous Group (pVOG) [38] as detected by
HMMscan (full sequence E value cutoff of 1-e05) as
implemented in HMMER v3.1b1 [39], or contain at least
one gene from a known human virus as detected by
BLASTp as implemented BLAST+ v2.2.28 [37] against
human viruses in the RefSeq database (E value cutoff of
1-e10) [40]. Integrase genes were detected by counting
any hits to a pVOG that contains any gene annotated as
an integrase. This allowed for the inclusion of known vi-
ruses, putative viruses, potential novel viruses bearing
little to homology to known viruses, and partially assem-
bled low abundance viruses. The quality filtered reads
were then aligned to this contig set using bowtie2 v2.1.0
[41] using end-to-end alignment mode. A count table
was generated with samtools v0.1.19 [42], which was
then imported into R v3.3.1 for statistical analysis. In
order for a contig to be counted as present in a sample,
it needed to have at least a 25% breadth of coverage;
otherwise, counts were set to zero.
Alpha diversity and beta diversity were generated using
PhyloSeq v1.16.2 [43], which also was used for principal
coordinate analysis as implemented in Ape v3.5. PERMA-
NOVA as implemented in the Adonis function in the
Vegan package was used for associating distance matrices
with metadata factors. PERMANOVA as implemented in
the Adonis function in the Vegan package was used for
associating distance matrices with metadata factors.
Spearman correlation between samples was calculated
using the cor.test() function as implemented in R v3.3.1.
Viruses were classified to a taxonomic group by the
method previously utilised by Zuo et al. [8]. Briefly, amino
acid sequences from open read frames (ORFs) predicted
by Prodigal v2.6.3 [44] were matched against the UniProt
TrEMBL database as of December 4, 2017. Taxonomy
was then assigned to each contig based on the most abun-
dant taxa detected by protein BLAST. All statistical ana-
lysis was performed in R v3.3.1 throughout this study.
Additional files
Additional file 1: Table S1. Metadata and sample timeline for donors
and recipients. Donor and patient demographics are detailed as are the
faecal sampling time points (a tick denoting sample collection). In the
case of donors, additional samples were collected in order to correlate
with recipient timelines. This is an amended table from the study of
Jalanka et al. [4] in which the bacteriome in these individuals was
examined. (XLSX 11 kb)
Additional file 2: Figure S1. Viral alpha diversity. Alpha diversity
estimates per time point for the recipients compared with the donors for
(A) viral richness (Chao1) and (B) diversity (Shannon) are represented
using boxplots. Whiskers indicate the highest or lowest occurring value
within 1.5*IQR (interquartile range) of the upper or lower quartile. Paired
Wilcoxon rank sum test, p≤ 0.05 (*). (PDF 63 kb)
Abbreviations
FMT: Faecal microbiota transplantation; rCDI: Recurrent Clostridium difficile
infection; UC: Ulcerative colitis
Acknowledgements
We would like to thank the donors and patients for their participation.
Draper et al. Microbiome           (2018) 6:220 Page 7 of 9
Funding
This publication has emanated from research conducted with the financial
support of Science Foundation Ireland under Grant number SFI/12/RC/2273,
Academy of Finland (258439, 283088, and 304490), University of Helsinki,
Sigrid Juselius, and Paulo and Sohlberg Foundations as well as Helsinki and
Uusimaa Hospital District.
Availability of data and materials
Raw virome sequence data is deposited at Sequence Read Archive under
BioProject PRJNA446038. R scripts along with all input raw count and metadata are
available via FigShare (https://figshare.com/s/3907644b46b5edb706df). The scripts
for performing the taxonomic assignment of contigs has been implemented and
made available via Github (https://github.com/feargalr/Demovir).
Authors’ contributions
LAD performed the viral extractions and DNA library preparation, analysed
the results, and wrote the manuscript. FJR performed all bioinformatic
analyses and wrote the manuscript. MKS performed the viral extractions and
DNA library preparation. JJ analysed the data and drafted the manuscript. EM
and PA was involved in the original study concept design and acquisition of
data. RPR, RS, and CH were involved in the study design, interpretation of
data, critical review of the manuscript, and acquisition of funding. All authors
read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Hospital District of
Helsinki and Uusimaa Finland (DnroHUS124/13/03/01/11). Informed consent
was obtained from all participants.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1APC Microbiome Institute, University College Cork, Cork, Ireland. 2Present
Address: South Australian Health and Medical Research Institute, North
Terrace, Adelaide 5000, Australia. 3Immunobiology Research Program and
Department of Bacteriology and Immunology, Faculty of Medicine, University
of Helsinki, Helsinki, Finland. 4Departments of Gastroenterology and
Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.
Received: 17 May 2018 Accepted: 18 November 2018
References
1. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome.
Genome medicine. 2016;8(1):51.
2. Cho I, Blaser MJ. The human microbiome: at the interface of health and
disease. Nat Rev Genet. 2012;13(4):260.
3. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for
the treatment of Clostridium difficile infection: a systematic review. J Clin
Gastroenterol. 2014;48(8):693–702.
4. Jalanka J, Mattila E, Jouhten H, Hartman J, de Vos WM, Arkkila P, Satokari R.
Long-term effects on luminal and mucosal microbiota and commonly
acquired taxa in faecal microbiota transplantation for recurrent Clostridium
difficile infection. BMC Med. 2016;14(1):155.
5. Ogilvie LA, Jones BV. The human gut virome: a multifaceted majority. Front
Microbiol. 2015;6:918.
6. Barr JJ, Auro R, Furlan M, Whiteson KL, Erb ML, Pogliano J, Stotland A,
Wolkowicz R, Cutting AS, Doran KS. Bacteriophage adhering to mucus provide
a non–host-derived immunity. Proc Natl Acad Sci. 2013;110(26):10771–6.
7. Broecker F, Russo G, Klumpp J, Moelling K. Stable core virome despite
variable microbiome after fecal transfer. Gut Microbes. 2017;8(3):214–20.
8. Zuo T, Wong SH, Lam K, Lui R, Cheung K, Tang W, Ching JY, Chan PK, Chan
MC, Wu JC. Bacteriophage transfer during faecal microbiota transplantation
in Clostridium difficile infection is associated with treatment outcome. Gut.
2017. https://doi.org/10.1136/gutjnl-2017-313952.
9. Chehoud C, Dryga A, Hwang Y, Nagy-Szakal D, Hollister EB, Luna RA,
Versalovic J, Kellermayer R, Bushman FD. Transfer of viral communities
between human individuals during fecal microbiota transplantation. MBio.
2016;7(2):e00322–16.
10. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown
EM, Schroeter K, Allen-Vercoe E. Stool substitute transplant therapy for the
eradication of Clostridium difficile infection:‘RePOOPulating’ the gut.
Microbiome. 2013;1(1):3.
11. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA,
Cassidy L, Tholey A, Fickenscher H, Seegert D. Efficacy of sterile fecal filtrate
transfer for treating patients with Clostridium difficile infection.
Gastroenterology. 2017;152(4):799–811 e797.
12. Roux S, Enault F, Hurwitz BL, Sullivan MB. VirSorter: mining viral signal from
microbial genomic data. PeerJ. 2015;3:e985.
13. Zhang T, Breitbart M, Lee WH, Run J-Q, Wei CL, Soh SWL, Hibberd ML, Liu
ET, Rohwer F, Ruan Y. RNA viral community in human feces: prevalence of
plant pathogenic viruses. PLoS Biol. 2005;4(1):e3.
14. Conceição-Neto N, Deboutte W, Dierckx T, Machiels K, Wang J, Yinda KC,
Maes P, Van Ranst M, Joossens M, Raes J. Low eukaryotic viral richness is
associated with faecal microbiota transplantation success in patients with
UC. Gut. 2017. https://doi.org/10.1136/gutjnl-2017-315281.
15. Menzel P, Ng KL, Krogh A. Fast and sensitive taxonomic classification for
metagenomics with kaiju. Nat Commun. 2016;7:11257.
16. Virgin HW. The virome in mammalian physiology and disease. Cell. 2014;
157(1):142–50.
17. Dutilh BE, Cassman N, McNair K, Sanchez SE, Silva GG, Boling L, Barr JJ,
Speth DR, Seguritan V, Aziz RK. A highly abundant bacteriophage
discovered in the unknown sequences of human faecal metagenomes. Nat
Commun. 2014;5. https://doi.org/10.1038/ncomms5498.
18. Yutin N, Makarova KS, Gussow AB, Krupovic M, Segall A, Edwards RA,
Koonin EV. Discovery of an expansive bacteriophage family that
includes the most abundant viruses from the human gut. Nature
microbiology. 2018;3(1):38.
19. Goldberg E, Amir I, Zafran M, Gophna U, Samra Z, Pitlik S, Bishara J.
The correlation between Clostridium-difficile infection and human gut
concentrations of Bacteroidetes phylum and clostridial species. Eur J
Clin Microbiol Infect Dis. 2014;33(3):377–83.
20. Roux S, Krupovic M, Poulet A, Debroas D, Enault F. Evolution and diversity
of the Microviridae viral family through a collection of 81 new complete
genomes assembled from virome reads. PLoS One. 2012;7(7):e40418.
21. Lee ST, Kahn SA, Delmont TO, Shaiber A, Esen ÖC, Hubert NA, Morrison HG,
Antonopoulos DA, Rubin DT, Eren AM. Tracking microbial colonization in
fecal microbiota transplantation experiments via genome-resolved
metagenomics. Microbiome. 2017;5(1):50.
22. Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J,
Nieuwdorp M, Salojärvi J, Voigt AY. Durable coexistence of donor and
recipient strains after fecal microbiota transplantation. Science. 2016;
352(6285):586–9.
23. Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, Young VB.
Recovery of the gut microbiome following fecal microbiota transplantation.
MBio. 2014;5(3):e00893–14.
24. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-
throughput DNA sequence analysis reveals stable engraftment of gut
microbiota following transplantation of previously frozen fecal bacteria. Gut
Microbes. 2013;4(2):125–35.
25. Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F, Gordon JI.
Viruses in the faecal microbiota of monozygotic twins and their mothers.
Nature. 2010;466(7304):334.
26. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R,
Sokol H, Arkkila P, Pintus C, Hart A. European consensus conference on
faecal microbiota transplantation in clinical practice. Gut. 2017. https://doi.
org/10.1136/gutjnl-2016-313017.
27. Tariq R, Weatherly R, Kammer P, Pardi DS, Khanna S. Donor screening
experience for fecal microbiota transplantation in patients with recurrent
Cdifficile infection. Journal of clinical gastroenterology. 2018;52(2):146–50.
28. Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, van
den Bogaerde J, Leong RW, Connor S, Ng W. Donor recruitment for
fecal microbiota transplantation. Inflamm Bowel Dis. 2015;21(7):1600–6.
29. Costello SP, Tucker EC, La Brooy J, Schoeman MN, Andrews JM. Establishing
a fecal microbiota transplant service for the treatment of Clostridium
difficile infection. Clin Infect Dis. 2015;62(7):908–14.
Draper et al. Microbiome           (2018) 6:220 Page 8 of 9
30. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Kambal A,
Monaco CL, Zhao G, Fleshner P. Disease-specific alterations in the enteric
virome in inflammatory bowel disease. Cell. 2015;160(3):447–60.
31. Lim ES, Zhou Y, Zhao G, Bauer IK, Droit L, Ndao IM, Warner BB, Tarr PI, Wang
D, Holtz LR. Early life dynamics of the human gut virome and bacterial
microbiome in infants. Nat Med. 2015;21(10):1228.
32. Krishnamurthy SR, Wang D. Origins and challenges of viral dark matter. Virus
Res. 2017;239:136–42.
33. Andrews S. FastQC: a quality control tool for high throughput sequence
data; 2010.
34. Martin M. Cutadapt removes adapter sequences from high-throughput
sequencing reads. EMBnet journal. 2011;17(1):10–2.
35. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
sequence data. Bioinformatics. 2014;30(15):2114–20.
36. Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. metaSPAdes: a new
versatile metagenomic assembler. Genome Res. 2017;27(5):824–34.
37. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K,
Madden TL. BLAST+: architecture and applications. BMC bioinformatics.
2009;10(1):421.
38. Grazziotin AL, Koonin EV, Kristensen DM. Prokaryotic virus orthologous
groups (pVOGs): a resource for comparative genomics and protein family
annotation. Nucleic Acids Res. 2016. https://doi.org/10.1093/nar/gkw975.
39. Eddy SR. Accelerated profile HMM searches. PLoS Comput Biol. 2011;7(10):
e1002195.
40. O’Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, Rajput B,
Robbertse B, Smith-White B, Ako-Adjei D. Reference sequence (RefSeq)
database at NCBI: current status, taxonomic expansion, and functional
annotation. Nucleic Acids Res. 2015;44(D1):D733–45.
41. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat
Methods. 2012;9(4):357.
42. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis
G, Durbin R. The sequence alignment/map format and SAMtools.
Bioinformatics. 2009;25(16):2078–9.
43. McMurdie PJ, Holmes S. Phyloseq: an R package for reproducible interactive
analysis and graphics of microbiome census data. PLoS One. 2013;8(4):e61217.
44. Hyatt D, Chen G-L, LoCascio PF, Land ML, Larimer FW, Hauser LJ. Prodigal:
prokaryotic gene recognition and translation initiation site identification.
BMC bioinformatics. 2010;11(1):119.
Draper et al. Microbiome           (2018) 6:220 Page 9 of 9
